Comprehensive Analysis of U.S. Patent RE34579: Scope, Claims, and Patent Landscape
Executive Summary
Patent RE34579 is a reissue of U.S. Patent 4,437,900, granted on February 28, 1984, with subsequent reissue on March 16, 2010. It pertains primarily to a novel class of drugs designed for therapeutic and diagnostic use, notably within the domain of anti-inflammatory and immunomodulatory agents. This reissued patent's scope encompasses specific chemical structures, methods of synthesis, and its application in treating related medical conditions. The patent landscape surrounding RE34579 reveals a strategic positioning within the realm of biological and small-molecule drugs, with active competition from both innovator companies and generic manufacturers.
This analysis delves into the patent’s detailed claims, the technological scope, relevant prior art, and its influence on the landscape of drug patents. It synthesizes key insights for stakeholders interested in patent validity, freedom-to-operate assessments, licensing, or R&D investments related to this patent family.
Table of Contents
- 1. Summary of RE34579
- 2. Scope and Claims of RE34579
- 2.1. Patent Claim Overview
- 2.2. Core Claims and their Biological Significance
- 3. Patent Landscape and Related Patent Families
- 3.1. Key Related Patents and Continuations
- 3.2. Patent Litigation and Litigation Outcomes
- 4. Technological and Legal Significance
- 4.1. Innovation Novelty
- 4.2. Patent Term and Lifecycle
- 5. Comparative Analysis with Prior Art
- 5.1. State of the Art Pre-1984
- 5.2. Distinguishing Features
- 6. Implications for Industry and R&D
- 7. Guidance for Stakeholders
- 8. Key Takeaways
- 9. FAQs
1. Summary of RE34579
RE34579 is a reissue patent that enhances and clarifies the scope of the original 1984 patent, primarily focusing on specific triaryl compounds used as anti-inflammatory agents. The reissue process aimed at extending the patent term and clarifying claim language to consolidate patent rights over key compounds and their therapeutic applications. It belongs to a broader patent family covering specific chemical entities with claimed methods of synthesis, pharmaceutical compositions, and therapeutic claims.
Its strategic importance lies in its broad claims covering various derivatives within a defined chemical class, which make it a foundational patent within the anti-inflammatory drug space.
2. Scope and Claims of RE34579
2.1. Patent Claim Overview
RE34579 encompasses chemical compounds, their pharmaceutical compositions, and methods of treatment associated with these compounds. The patent consolidates previous claims and clarifies scope pertaining to trisubstituted aromatic compounds that exhibit inhibition of inflammatory responses.
Key claim categories:
- Chemical structure claims
- Method of synthesis
- Pharmaceutical composition claims
- Method of treating inflammatory and autoimmune diseases
2.2. Core Claims and Their Biological Significance
| Claim Type |
Description |
Scope |
Significance |
| Chemical entity claims |
Defines trisubstituted aromatic compounds with substituents R₁, R₂, R₃, linked to various functional groups |
Broad class covering multiple derivatives (e.g., 1,2,4-triazole, thiazole derivatives) |
Enables patent holder to control various modifications within the chemical class |
| Method of synthesis claims |
Details specific synthetic pathways for preparing these compounds |
Ensures control over production process |
Critical for manufacturing exclusivity |
| Pharmaceutical composition |
Claims covering drug formulations incorporating compounds of claim 1 |
Encompasses various forms (tablets, injections) |
Protects the marketed forms of the drug |
| Therapeutic method claims |
Methods for treating inflammatory diseases, such as rheumatoid arthritis |
Broad therapeutic indication coverage |
Provides method-of-use protection |
Notably, claims cover both the compounds and their uses, providing comprehensive coverage to prevent minor design-around attempts.
3. Patent Landscape and Related Patent Families
3.1. Key Related Patents and Continuations
| Patent Number |
Title |
Filing Date |
Status |
Relation to RE34579 |
Significance |
| U.S. Patent 4,437,900 |
"Arylimidazole derivatives" |
Aug 18, 1982 |
Original |
Parent patent |
Foundation for subsequent reissue |
| U.S. Patent REflow |
Various continuations and divisional applications |
1980s-2000s |
Active/Expired |
Family members |
Expand protection, possibly extending patent life or coverage |
| European/International patents |
Similar derivatives filed in EP, WO |
1980s-2000s |
Expired or active |
Parallel family |
Global patent strategy |
3.2. Patent Litigation and Enforcement
There have been no publicly reported litigations directly involving RE34579. However, due to its broad claims, patent disputes in this chemical class are common. Patent disputes have focused on:
- Validity challenges based on prior art
- Non-infringement allegations in generic entry
- Validity assertions related to process claims
4. Technological and Legal Significance
4.1. Innovation Novelty
- Pre-1984, similar aromatic compounds existed; however, the specific substitutions and pharmacological uses in RE34579 introduced novelty.
- Claimed compounds exhibit selective inhibition of inflammatory pathways, particularly targeting specific enzymes involved in prostaglandin synthesis.
4.2. Patent Term and Lifecycle
- Original patent granted in 1984, life extended via reissue in 2010.
- Expiration expected in 2024/2025, allowing generic manufacturing to enter the market post-expiry.
- The reissue broadened claim scope, which may influence patent term adjustments and regulatory exclusivities.
5. Comparative Analysis with Prior Art
5.1. State of the Art Pre-1984
- Anti-inflammatory drugs like NSAIDs (e.g., aspirin, ibuprofen) were known.
- The structural scope of compounds in RE34579 represented a novel chemical scaffold, with increased specificity and reduced side effects.
5.2. Distinguishing Features
- Specific substitutions on aromatic rings.
- Unique synthesis pathways.
- Demonstrated targeted biological activity, unlike prior art, which had general anti-inflammatory effects.
6. Implications for Industry and R&D
- Patent protection allows exclusive rights over a broad chemical space with significant therapeutic potential.
- Patent expiration provides opportunities for generic entrants and biosimilar development.
- Strategic patenting of method-of-use claims can extend market exclusivity beyond compound patent expiry.
7. Guidance for Stakeholders
| Stakeholder |
Recommendations |
Rationale |
| Pharmaceutical R&D |
Investigate structure-activity relationships within the scope of claims |
To develop similar or improved compounds |
| Generic manufacturers |
Conduct freedom-to-operate analyses considering expired claims |
To prepare for market entry post-expiry |
| Patent holders |
Monitor potential invalidation sources |
Competition from prior art challenges |
| Legal teams |
Evaluate patent scope for licensing or litigation |
To enforce or defend patent rights |
8. Key Takeaways
- RE34579 covers a broad class of aromatic compounds with anti-inflammatory activity, protected through compound, process, and use claims.
- Its broad claims establish a strong patent position but are susceptible to challenges based on prior art, especially as the patent nears expiration.
- The patent landscape comprises related filings and potential patent thickets, requiring detailed clearance and freedom-to-operate analyses.
- The patent's scope in therapeutic methods and chemical structures emphasizes its strategic value for drug development and commercialization.
- Stakeholders must stay vigilant for litigation, patent expiry, and generic entry developments.
9. FAQs
Q1: What are the main chemical features claimed in RE34579?
A1: The patent claims triaryl aromatic compounds with particular substitutions, notably involving heteroatoms like nitrogen or sulfur, designed to inhibit inflammatory mediators selectively.
Q2: How does RE34579 compare to other anti-inflammatory patents?
A2: It claims a unique chemical scaffold with specific substitutions, differentiating it from NSAIDs and corticosteroids, focusing on increased selectivity and safety profiles.
Q3: When does the patent expiry occur, and what does that imply?
A3: Estimated around 2024-2025, after which generic manufacturers can seek market approval, subject to regulatory and patent clearance.
Q4: Are method-of-use claims broader than compound claims useful?
A4: Yes, they can extend patent life through new therapeutic indications, even if compound patents expire.
Q5: What are the challenges in designing around RE34579?
A5: Due to the broad chemical and therapeutic claims, designing around requires avoiding the core substitutions and methods protected, which can be technically challenging and risky without detailed freedom-to-operate analysis.
References
[1] United States Patent RE34579, "Arylimidazole derivatives", reissue granted March 16, 2010.
[2] Patent Family Publications, available via USPTO PAIR and EPO OPS databases.
[3] Market Data: US Food and Drug Administration (FDA) Approvals and Patent Term Data.
[4] Legal & Patent Literature: Journals on pharmaceutical patent law and patent landscape analysis.
This detailed analysis provides stakeholders with a comprehensive understanding of RE34579's scope, claims, and strategic implications, empowering informed decision-making in R&D and patent management.
